



Contact: Barbara Chung
DNArgus Corporate Communications
comms@dnargus.com

Life1K Serum New Drug Application Submitted to DDEA

GROVER'S LANE, May 20 – DNArgus, a world-class biopharmaceutical and health services company, today announced that it has submitted a new drug application for its novel life extension therapy Life1K to the DDEA. Life1K is an oral liquid nutraceutical that is administered once a month.

“The Life1K submission is a milestone for DNArgus and mankind,” said Dr. Dan Collins, Founder & CEO of DNArgus. “Once Life1K becomes widely available, humans will enjoy longer life spans and increased resistance to disease.”

Life1K was studied extensively over a five-year period in two major clinical trials, EXTEND and DREAM. 77% of elderly patients in both trials significantly improved their health and vitality after one year of treatment.

The most common side effects associated with Life1K treatment include headache, nausea, migraines, blurred vision and constipation. .005% of patients in DREAM and EXTEND developed cancer of the esophagus. In all cases, the cancer was cured after standard medical treatment.

DNArgus expects the DDEA to make a decision on Life1K within six to eight months.

About DNArgus

DNArgus is a world-class biopharmaceutical and health services company specializing in the development and commercialization of life extension therapies. Our flagship cryobooth, AICryogenesis II, is the safest and most well-studied product of its kind in the world. Learn more about the company at www.DNArgus.com.

#